3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Other solid neoplasm
1
Conditions
Advanced Solid Tumors
3
Solid Tumor, Adult
1
Solid Tumor
1
Pancreatic Neoplasms
1
Mesothelioma
1
KRAS p.G12C Mutant Advanced Solid Tumors
1
Carcinoma, Non-Small-Cell Lung
1
Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
1
Advanced Solid Tumor
1
Interventions
Cyclophosphamide
6
pembrolizumab
5
fludarabine
4
fludarabine phosphate
2
amatuximab
2
SS1(dsFv)PE38
2
tocilizumab
1
sotorasib
1
sargramostim
1
enzalutamide
1
entinostat
1
defactinib
1
bemcentinib
1
aldesleukin
1
alanosine
1
Tablets
1
Sorafenib
1
Sirolimus
1
Quality of Life
1
Polymerase Chain Reaction
1
Pentostatin
1
Pemetrexed
1
Patient Reported Outcome Measures
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Microarray Analysis
1
Ipilimumab
1
Interleukin-12 Subunit p35
1
Interferon-gamma
1
Interferon-alpha
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
sotorasib
×
Other solid neoplasm
×
Clear all
NCT07563738
2026-05-04
TEADCO
Orion Corporation, Orion Pharma
Phase 1/2
Recruiting
229 enrolled